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Introduc>on
Asthma	is	one	of	the	most	prevalent	chronic	disorder	worldwide,	
aﬀecFng	235	million	people.	This	represents	a	serious	public	health	
issue	associated	with	high	health	costs,	mainly	due	to	the	diagnosis	and	
treatment.	A	European	study	has	esFmated	the	cost	of	asthma	to	19.3	
billion	euros/year.	Asthma	is	characterized	by	an	inﬂammaFon	of	the	
airways,	involving	several	underlying	mechanisms.	Induced	sputum	is	
the	gold	standard	method	to	assess	bronchial	inﬂammaFon.	However,	
this	approach	is	invasive	and	not	widely	available.	In	addiFon,	current	
therapies	remain	ineﬀecFve	in	a	large	proporFon	of	paFents.	For	these	
reasons,	the	characterizaFon	of	diﬀerent	inﬂammaFon	phenotypes	(i.e.	
eosinophilic,	neutrophilic,	paucigranulocyFc,	mixed-granulocyFc	
asthma)	is	of	great	importance	to	provide	personalized	treatment.
Methods
VolaFle	organic	compounds	from	breath	of	245	asthmaFc	paFents	
covering	a	range	of	four	diﬀerent	asthma	phenotypes	were	analyzed.	
The	breath	samples	were	collected	into	5	L	Tedlar®	bags.	Thermal	
desorpFon	coupled	with	comprehensive	two-dimensional	gas	
chromatography	(GC×GC)	–	high	resoluFon	Fme-of-ﬂight	mass	
spectrometry	was	applied	for	the	analysis.	In	this	context	of	complex	
mixtures	analysis,	GC×GC	oﬀers	a	powerful	soluFon	to	obtain	a	
complete	overview	of	the	samples’	composiFon.	To	handle	the	
complexity	of	generated	data,	quality	control	(QC)	protocol	was	
established	to	insure	the	proper	use	of	the	analyFcal	instrument.	
Internal	standards	were	injected	on	a	regular	basis,	every	30	samples,	to	
monitor	analyFcal	variaFons,	i.e.	1op	and	2ⁿr	retenFon	Fmes	and	VOCs	
intensiFes.
Preliminary	Data
The	data	were	pre-process	using	large	scale	alignment	tool.		
Subsequently,	the	data	were	split	between	training	and	test	(60-40%).	
Random	forest	algorithm	was	used	to	invesFgate	the	ability	of	exhaled	
breath	VOCs	to	disFnguish	between	the	inﬂammatory	proﬁles.	The	
random	forest	algorithm	was	built	on	7	signiﬁcant	features	highlighted	
in	a	ﬁrst	discovery	study	performed	on	an	independent	cohort	of	276	
paFents.	ROC	curves	were	constructed	to	evaluate	the	classiﬁcaFon	
performance	in	pair-classiﬁcaFon	scenario.	The	AUROC	classiﬁcaFons	
reached	0.71,	0.68	and	0.70	with	70%,	60%	and	64%	of	accuracy.	The	
predicFon	accuracy	using	VOC	measurement	was	similar	to	the	accuracy	
of	blood	eosinophil	levels	and	exhaled	nitric	oxide	(FeNO)	levels	that	are	
commonly	used	in	clinical	pracFce.	In	addiFon,	the	combinaFon	of	
blood	eosinophil	counts,	FeNO	and	VOCs	measurements	gave	the	best	
predicFon	accuracy	of	76%.	VOCs	also	enabled	the	idenFﬁcaFon	of	
sputum	neutrophilia	in	the	whole	populaFon	of	asthmaFcs	with	similar	
staFsFcal	power	than	isolated	markers	(FeNO,	blood	eosinophils)	used	
to	predict	sputum	eosinophilia.	Possible	cofounding	factors	such	as	
smoking,	inhaled	corFcosteroid	usage,	age	and	BMI	were	evaluated,	and	
no	interference	was	highlighted.	This	ﬁrst	large-scale	conﬁrmatory	study	
shows	that	breath	VOCs	analysis	is	an	eﬃcient	approach	for	asthma	
phenotyping	and	is	going	to	lead	to	further	development	in	clinical	
diagnosis.
Novel	Aspect
This	work	is	a	step	forward	for	designing	exhaled	air	inﬂammometers	as	
clinician	use	glucometers	in	diabetes,	to	adapt	treatments.	
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